[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"uterine-cervical-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:uterine-cervical-neoplasm":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,70,93,128],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100605593","phase-3-a-clinical-trial-to-assess-the-effectiveness-of-nrf2-activator-oral-sodium-copper--chlophyllin--in-locally-advanced-cervical-cancer-to-reduce-late-radiotherapy-toxicity-100605593",false,"NCT07164534","A Clinical Trial to Assess the Effectiveness of NRF2 Activator (Oral Sodium-copper- Chlophyllin ) in Locally Advanced Cervical Cancer to Reduce Late Radiotherapy Toxicity.","A Phase III Trial to Assess the Effectiveness of NRF2 Activator (Oral Sodium-copper- Chlophyllin ) in Locally Advanced Cervical Cancer to Reduce Late Radiotherapy Toxicity. (CHOC-LATE Trial)","CHOC-LATE","Inclusion Criteria:\n\n* Female subjects aged 18 years or above with histologically proven locally advanced squamous cell or adenocarcinoma of the cervix\n* Subjects eligible for RT and planned for definitive RT +\u002F- chemotherapy with brachytherapy.\n* Subjects who exceed the dose constraints of:\n\n  * Rectum\u002Fsigmoid D 2cm³ EQD2 ³ by more than 70 Gy, or\n  * Bladder D 2cm³ EQD2 ³ more than 80 Gy\n* Subjects with adequate haematological, renal, hepatic and coagulation profiles and laboratory parameters within the following ranges:\n\n  * Haemoglobin: ≥ 8 g\u002Fdl\n  * ANC ≥ 1,500\u002Fmm\\^3\n  * Platelet count 100,000\u002Fmm\\^3\n  * Creatinine Clearance: ≥ 50 ml\u002Fmin (as per Cockcroft-Gault formula)\n  * Bilirubin: ≤ 2 x Upper limit of normal (ULN)\n  * AST and ALT: ≤ 1.5 x ULN\n* Subjects willing and able to comply with all study requirements, including treatment (e.g. able to swallow tablets), timing and\u002For nature of required assessments\n* Ability to understand and willingness to sign an informed consent document\n\nExclusion Criteria:\n\n* Subjects with known hypersensitivity or contraindication to the study drug or to any known component of the study drug formulation\n* Subjects with clinically significant decreased hematologic reserves, with major organ failure, severe electrolyte or metabolic abnormalities, any active infection or any other medical condition that may interfere with the ability to receive study treatment\n* HIV positive patients\n* Subjects with a history of blood dyscrasias\n* Subjects consuming any other concurrent investigational agents\n* Subjects with any other previous or current malignancy or RT that is likely to interfere with the protocol treatment, or any other condition which, according to the principal investigator, might make an individual unsuitable for this study\n* Subjects participating in any other clinical study within 90 days before enrolment in the study\n* Subjects on active anti-coagulant treatment","FEMALE","18 Years",{"count":20,"type":21},316,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Cervical cancer is the second most common cancer in Indian women, and most patients are diagnosed at advanced stages.\n\nThe standard treatment for these stages is concurrent chemoradiotherapy, but this can cause long-term side effects such as bladder inflammation, strictures, ulcers, and tissue damage, which negatively impact patients' quality of life.\n\nPrevious studies have shown that oral sodium-copper-chlorophyllin can help reduce radiation-related side effects in rectal, prostate, and cervical cancer patients. However, no study has compared side effects between patients receiving standard follow-up care and those taking sodium-copper-chlorophyllin during follow-up.\n\nWe hypothesize that the use of sodium-copper-chlorophyllin as a short-duration adjuvant is associated with reduced incidence of late grade 2 or higher gastrointestinal and genitourinary toxicities compared to patients receiving standard-of-care follow-up.",[27],"Uterine Cervical Neoplasm",[29,30,31,32],"cervix cancer","radiation-related adverse effects","radiation","sodium-copper-chlorophyllin","NOT_YET_RECRUITING","2026-02-03",{"date":36,"type":37},"2026-02-04","ACTUAL",{"date":39,"type":21},"2026-03",{"date":41,"type":21},"2030-09",{"name":43,"class":44},"Tata Memorial Hospital","OTHER_GOV",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100559174","cervical-boost-by-ablative-stereotactic-radiotherapy-sabr-vs-brachytherapy-in-patients-with-cervical-carcinoma-100559174","NCT06560697","Cervical Boost by Ablative Stereotactic Radiotherapy (SABR) vs Brachytherapy in Patients With Cervical Carcinoma","Randomized Phase II Study to Measure the Safety and Efficacy of Concomitant CT\u002FRT Followed by Ablative Stereotactic Radiotherapy (SABR) vs Brachytherapy in Patients With Cervical Carcinoma in Clinical Stage IB3-IIIC1 at INCAN","SABRVICAL","Inclusion Criteria:\n\n1. People with cervical cancer \\>18 years of age.\n2. Signed informed consent form approved by the regulatory committees of both institutes and, obtained before each procedure related to the protocol, and that is not considered part of the normal care of the patient.\n3. Able to comply with scheduled visits, treatment schedules, laboratory and imaging studies, and completing quality of life questionnaires.\n4. Histological confirmation of CaCu and staged as IB3-IIIC1.\n5. Squamous cell, adenosquamous, or adenocarcinoma histology.\n6. No prior treatment for cervical cancer.\n7. With disease measurable by CT, MRI, or PET\u002FCT according to REC 1.1 criteria. This measurement must be carried out 28 days before randomization.\n8. Functional status of 0-2 according to WHO criteria.\n9. Charlson Comorbidity Index of 1-4\n10. Candidates to receive cisplatin.\n11. Normal hematological, kidney, and hepatic function according to:\n\n    Hematological:\n\n    Hemoglobin equal to or \\>10g\u002FL. (With the possibility of transfusion prior to treatment to reach this hemoglobin level).\n\n    Leukocytes \\>4000\u002Fmm3. Platelets\\>100,000mm3. Neutrophils \\>1500 \u002F μL\n\n    Hepatic:\n\n    Total bilirubin \\\u003C1.5 X times the normal value. Transaminases \\\u003C1.5 X times the normal value.\n\n    Renal:\n\n    Creatinine \\\u003C1.3mg\u002Fdl or creatinine clearance \\> 40 mL\u002Fminute (using the Cockcroft\u002FGault formula).\n\n    Women: DepCr = (140 - Age in years) x Weight in kg x 0.85\n\n    \\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_ 72 x Serum Creatinine in mg\u002FdL Men: DepCr = (140 - Age in years) x Weight in kg x 1.00\n\n    \\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_ 72 x Serum Creatinine in mg\u002FdL\n12. Chest tomography without metastatic disease or infectious diseases.\n13. Negative pregnancy test in women of childbearing age.\n14. Not a candidate for another clinical trial within the institution.\n\nExclusion Criteria:\n\n1. Patients with small-cell carcinoma or other rare histologies (glassy cell carcinoma, melanoma, sarcomas, lymphomas)\n2. Patients with non-measurable disease.\n3. Patients in whom pregnancy is confirmed during the recruitment procedure.\n4. Clinical stages IIIC2-IVB.\n5. Serious infections or diseases that can be reactivated with the use of chemotherapy or that could limit its use (hepatitis or HIV).\n6. Pre-existing neuropathy of any etiology.\n7. Concomitant treatment with another experimental drug.\n8. Mental illnesses: With the intention of maximizing adherence to the study, those patients who are at risk of imminent physical aggression (evident during the interview), have intellectual disabilities or autism, and who come for consultation due to coercion will not be included in the study. their accompanying Severe major depressive disorder, with or without psychotic symptoms; patients in whom a psychiatric diagnosis coexists in addition to the abuse of some recreational substance, eating disorders, schizophrenia, or Bipolar-type Schizoaffective Disorder.\n9. Grade 3 obesity with body mass index \\>40kg\u002Fm2 according to the World Health Organization: Patients treated with pelvic radiotherapy and a body mass index \\>40kg\u002Fm2 are associated with a decrease in quality of life due to sexual, intestinal, genitourinary alterations, as well as greater toxicity due to oncological treatments offered such as intracavitary brachyter in which the positioning of the equipment in the vaginal area is significantly difficult in sedated patients. Patients with grade III obesity will not be included.\n10. Any patient who is absent from follow-up for 5 subsequent appointments will be excluded from the study.\n11. History of total or partial hysterectomy.\n12. Patients with a history of neoadjuvant chemotherapy or use of another antineoplastic drug differ from cisplatin (40 mg\u002Fm2).\n13. History of use of Bevacizumab to manage a pathology other than CC or intention to use this drug as part of the treatment of CC.\n\n15\\. Charlson Comorbidity Index \\>5 16. Synchronous Cancer except non-melanoma Skin Cancer. 17. History of pelvic irradiation for metachronous cancer. 18. Inflammatory bowel disease or collagen diseases. 19. Patients with severe immunosuppression (transplant or treatment with immunosuppressive drugs).\n\n20\\. Patients who do not sign the informed consent form. 21. Suspected alcohol or recreational drug abuse. 22. Participation in any other clinical trial in the last 90 days prior to protocol recruitment.\n\n23\\. Any illness or disability not covered by the exclusion criteria that, in the researchers' opinion, may put the patient's safety and compliance with the protocol at risk.\n\n24\\. Patients with a percentage of rectal circumference receiving a dose of 15Gy \\>62.7%",{"count":54,"type":21},84,[56],"NA","Background Cervical cancer (CaCu) is the fourth cause of death in women. In patients with locally advanced disease, the treatment of choice is CT\u002FRT, followed by additional boosting with brachytherapy (BT). There is an international decrease in the use of this technique due to financial restrictions. Given the difficulties in using brachytherapy as a boost, several series have described promising results in local control using boost with highly conformal techniques such as stereotactic body radiotherapy (SBRT). On the other hand, prospective studies are scarce and with controversial results. No study has been published that directly compares three-dimensional intracavitary SBRT and BT. In this clinical trial, the researchers aim to demonstrate that boosting with SBRT is not inferior to intracavitary brachytherapy in patients with CC.\n\nMethodology\n\nPrimary Objective:\n\nTo evaluate the safety and efficacy of concomitant CT\u002FRT followed by Ablative Body Stereotactic Radiotherapy (SBRT) vs Brachytherapy in patients with Cervical Cancer in clinical stage IB3-IIIC1 at INCan.\n\nSecondary Objectives:\n\nThe purpose of this study is to evaluate quality of life, local efficacy (local control and time to local recurrence), overall survival, disease-free survival, and time to distant recurrence.\n\nStudy Design:\n\nSABRVICAL is a meticulously designed randomized two-arm open-label phase II study to compare QT\u002FRT + SBRT vs QT\u002FRT + Brachytherapy. It will include patients with IB3-IIIC1 CaCu \\>18 years of age with adequate renal function. They will be randomized 1:1 to the experimental arm or the standard arm.\n\nExpected Results and Outlook With this study, we aim to assess that the safety and efficacy of concomitant QT\u002FRT with cisplatin followed by SBRT is not inferior to boost with brachytherapy in patients with CaCu IB3-IIIC1. The potential impact of this study is significant, as it could provide new treatment options for hospitals that do not have brachytherapy or have a prolonged waiting list for this procedure.",[27],"RECRUITING","2025-10-01",{"date":62,"type":37},"2025-10-07",{"date":64,"type":37},"2024-05-15",{"date":66,"type":21},"2030-12-31",{"name":68,"class":44},"National Institute of Cancerología",1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":69},"100583582","ctdna-guided-first-line-immuno-de-escalation-therapy-for-ivb-stage-and-recurrent-cervical-cancer-100583582","NCT06878196","ctDNA-guided First-line Immuno-de-escalation Therapy for IVB-stage and Recurrent Cervical Cancer","ctDNA-guided First-line Immuno-de-escalation Therapy for Stage IVB and Recurrent Cervical Cancer: A Prospective, Single-arm, Multicenter Phase II Clinical Trial","Inclusion Criteria:\n\n* Clinically diagnosed as stage IVB primary treatment and recurrent cervical cancer patients (this relapse has not been systematically treated); Histologically or cytologically confirmed recurrent or metastatic cervical cancer, pathological types are squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma; Age ≥18 years old and ≤75 years old, female; Signed written informed consent form, and able to comply with the visitation and related procedures specified in the protocol; Has not received systematic treatment for primary stage IVB or this relapse; Has at least one measurable lesion (RECIST 1.1 version); ECOG performance status 0-1; Estimated survival time ≥3 months; Menopausal trial participants must agree to use effective contraceptive measures during the trial; pregnant women must have a negative serum or urine pregnancy test.\n\nGood organ function:\n\nHematology (subjects will not be allowed to receive blood transfusion or growth factor support within 7 days of starting the study): i. Neutrophil count (ANC) ≥ 1.5 × 10\\^9 \u002FL (1,500\u002Fmm\\^3); ii. Platelet count ≥ 100 × 10\\^9 \u002FL (100,000\u002Fmm\\^3); iii. Hemoglobin ≥ 9.0 g\u002FdL.\n\nKidney:\n\ni. Serum creatinine (SCr) ≤ 1.5 × ULN or creatinine clearance (CrCl) calculated value ≥ 50 mL\u002Fmin \\* using the Cockcroft-Gault formula to calculate CrCl; if cisplatin is planned to be used in combination, CrCl ≥ 60 mL\u002Fmin;\n\nLiver:\n\ni. Serum total bilirubin (TBil) ≤ 1.5 × ULN; for subjects with liver metastasis or with evidence of Gilbert's disease, TBil ≤ 3 × ULN; ii. AST and ALT ≤2.5 × ULN; for subjects with liver metastasis, AST and ALT ≤ 5 × ULN; iii. Serum albumin ≥ 28 g\u002FL.\n\nCoagulation:\n\ni. International normalized ratio and activated partial thromboplastin time ≤ 1.5 × ULN (unless the subject is undergoing anticoagulant treatment, and the coagulation parameters (PT\u002FINR and aPTT) are within the expected range of anticoagulant treatment at screening) 11. Menopausal trial participants must agree to use effective contraceptive measures during the trial; pregnant women must have a negative serum or urine pregnancy test.\n\nExclusion Criteria:\n\n* Patients with pathological types other than squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma (e.g., small cell carcinoma, clear cell carcinoma, etc.).\n\nPatients with clinically significant hydronephrosis of the renal pelvis, judged by the investigator as not relievable by nephrostomy or ureteral stent placement. Presence of central nervous system metastasis or carcinomatous meningitis.\n\nPatients with other active malignant tumors within 3 years prior to the first dose of medication, except for locally curable tumor types that are considered cured, such as cutaneous squamous cell carcinoma, cutaneous basal cell carcinoma, superficial bladder carcinoma, primary breast cancer.\n\nWithin 4 weeks prior to the first dose of medication, patients who have received the last cycle of concurrent radiochemotherapy aimed at radical or neoadjuvant\u002Fadjuvant purposes; within 2 weeks prior to the first dose of medication, patients who have received palliative radiotherapy (e.g., for bone metastasis); within 2 weeks prior to the first dose of medication, patients who have received drugs with immunomodulatory effects (e.g. thymic peptides, interferons, interleukin-2); within 2 weeks prior to the first dose of medication, patients who have received traditional Chinese patent medicine for anti-tumor adaptation.\n\nPatients who have previously received immune checkpoint inhibitors (e.g., anti PD-1 antibodies, anti PD-L1 antibodies, anti CTLA-4 antibodies, etc.) or any treatment targeting tumor immune mechanisms (e.g., antibodies targeting ICOS, CD40, CD137, GITR, OX40 targets, etc.).\n\nWithin 4 weeks prior to the first dose of medication, patients who have undergone major surgery (determined by the investigator), open biopsy, or significant trauma; or patients who require major surgical treatment during the study period and cannot tolerate medication.\n\nPatients with active or potentially recurrent autoimmune diseases; the following are excluded: vitiligo, alopecia, psoriasis, or eczema that do not require systemic treatment; hypothyroidism caused by autoimmune thyroiditis, requiring only stable dose hormone replacement treatment; type I diabetes requiring only stable dose insulin replacement treatment.\n\nWithin 14 days prior to the first dose of medication, patients who require systemic treatment with \\>10 mg\u002Fday prednisone or equivalent doses of glucocorticoid hormones or other immunosuppressive drugs; within 4 weeks prior to the first dose of medication, patients with severe infections, including but not limited to complications requiring hospitalization, sepsis, or severe pneumonia.\n\nActive or potentially recurrent systemic infections requiring systemic treatment (including active pulmonary tuberculosis and active syphilis infection), and who have used systemic antibacterial, antiviral, or antifungal drugs within 2 weeks prior to the first dose of medication; note: antiviral drugs for hepatitis B are excluded.\n\nActive hepatitis B virus carriers, non-active or asymptomatic hepatitis B virus (HBV) carriers (hepatitis B surface antigen \\[HBsAg\\] positive) with HBV DNA \\>1000 IU\u002FmL, and active hepatitis C virus carriers (note: non-active or asymptomatic carriers, after treatment and stable hepatitis B carriers with HBV DNA ≤ 1000 IU\u002FmL are allowed to enroll). Patients with cured hepatitis C are allowed to enroll.\n\nPatients with active or a history of inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis), active diverticulitis, presence of clinical manifestations of gastrointestinal obstruction, or those requiring routine parenteral fluid, parenteral nutrition, or nasogastric tube placement.\n\nSevere cerebrovascular or cerebrovascular diseases. Previous antineoplastic treatment toxicity not resolved, defined as toxicity not recovered to NCI CTCAE v5.0 ≤1 grade, or the levels specified in the inclusion\u002Fexclusion criteria (except for alopecia).\n\nPatients allergic to the investigational medication. Any condition that the investigator believes may pose a risk to receiving study medication treatment, or may interfere with the evaluation of the study medication or the safety or interpretation of the results of the study (e.g. patients with other serious diseases or psychiatric disorders, etc.)","75 Years",{"count":79,"type":21},20,[56],"This study aims to evaluate the clinical feasibility of first-line immunochemotherapy for stage IVB and recurrent cervical cancer guided by circulating tumor DNA (ctDNA), in order to explore the optimal treatment duration or criteria for discontinuation of first-line immunotherapy in patients with stage IVB cervical cancer or recurrent cervical cancer. To ensure the quality of the study, before the study begins, the research applicant and participants jointly discuss and formulate the research plan. Necessary steps should be taken during the design and implementation stages of the study to ensure that the collected data is accurate, consistent, complete, and credible.",[27],"2025-03-13",{"date":85,"type":37},"2025-03-14",{"date":87,"type":21},"2025-03-10",{"date":89,"type":21},"2028-12",{"name":91,"class":92},"Obstetrics & Gynecology Hospital of Fudan University","OTHER",{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":17,"minAge":99,"maxAge":77,"enrollmentInfo":100,"targetDuration":4,"studyType":22,"phases":102,"briefSummary":103,"conditions":104,"keywords":114,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":127},"100367261","research-project-on-reminders-and-self-sampling-can-increase-participation-in-gynecology-cell-sampling---preventive-examination-against-cervical-cancer-100367261","NCT04061967","Research Project on Reminders and Self-Sampling Can Increase Participation in Gynecology Cell Sampling - Preventive Examination Against Cervical Cancer.","Inclusion Criteria:\n\n* Women resident in Region Skane who either: 1) have had glandular cell transformation that has not been followed-up, 2) are older than 65 years and have had cell transformation that has not been followed-up or who have not participated in screening during the last 10 years, 3) women who have not been screened for more than 15 years.\n\nExclusion Criteria:\n\n* No exclusion except those who do not consent.","33 Years",{"count":101,"type":21},20000,[56],"Prevention of cervical cancer with cervical screening is one of the most successful screening activities in medicine. In Sweden, screening was implemented in the 1960s and has since prevented tens of thousands of women from having cervical cancer. Individual invitations to screening result in increased attendance therefore evaluating strategies for reaching women through invitations is particularly valuable. Women who regularly attend screening following an invitation reduce their risk of cervical cancer by as much as 90%. Of the women who are diagnosed with cervical cancer (about 550 women per year in Sweden), as many as 38% did not participate in the screening. Invitations for screening are sent to the entire population in Sweden aged 23-70. The current coverage of screening is 82.9%, which represents the proportion of women ages 23-70 who attend according to recommendations. In addition, many women are sporadic attenders who reduce their risk for cancer somewhat. The highest cancer risk is seen among those women who have never participated as well as women who have had a history of precancerous lesions or HPV infection but have not been followed-up. Cervical cancer is the first form of cancer for which there are approved molecular screening tests (HPV test). Unlike the older screening method (cytology), self-collected samples can be analyzed for HPV (the analysis method is so sensitive that it does not matter if the sample is not optimally taken).\n\nInvitations and reminders about cervical screening are sent by letter to the woman's home address (about 3 million letters per year in Sweden). This strategy results in a waste of resources and has a negative environmental impact. Regarding reminders, we have seen in previous research that the effect is not optimal. When sending a physical reminder letter to women who have not participated in more than 10 years (current routine), only 2% of the women invited came for sampling. Reminders with SMS are now standard for many businesses in society, such as car testing or dental appointments. It is inexpensive, saves the environment and there are studies that suggest it is more effective than sending physical letters. In this study, we intend to investigate whether SMS reminders, electronic letters, and physical letters for screening lead to increased participation and thus to a higher proportion of detected, treatable precursors of cervical cancer compared to before.",[105,27,106,107,108,109,110,111,112,113],"Cervical Cancer","Uterine Neoplasms","Genital Neoplasm","Genital Neoplasm, Female","Uterine Diseases","Genital Diseases, Female","Neoplasms by Site","Neoplasms","Uterine Cervical Disease",[115,116,117],"participation","self sampling","screening","2025-01-10",{"date":120,"type":37},"2025-01-14",{"date":122,"type":37},"2019-08-19",{"date":124,"type":21},"2030-06-01",{"name":126,"class":92},"Karolinska Institutet",6,{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":17,"minAge":136,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":22,"phases":140,"briefSummary":141,"conditions":142,"keywords":146,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":69},"100562054","developing-a-combined-molecular-screening-and-triage-test-for-cervical-cancer-in-self-samples-100562054","NCT06598176","Developing a Combined Molecular Screening and Triage Test for Cervical Cancer in Self-samples","Developing a Combined Molecular Screening and Triage Test for Cervical Cancer Based on Human Papillomavirus (HPV) Detection, Quantification, Genotyping and DNA Methylation in Self-samples (COMBISCREEN)","COMBISCREEN","Inclusion Criteria:\n\n* Female\n* 25 until 64 years old\n* Diagnosed with cervical cancer (CIN3+, irrespective of stage) OR in need of conization (irrespective of diagnostic or therapeutic purposes)\n* Has not started any form of cancer treatment prior to study enrollment\n* Written informed consent must be obtained from patient\n* Is able to understand the information brochure and what the study is about\n\nExclusion Criteria:\n\n* Women that underwent hysterectomy\n* Pregnant women or 6 weeks post-partum\n* Treatment for cervical (pre)cancer in the last 6 months before participation in the study\n* Participating in another interventional clinical study (where e.g., a medical device, drug, or vaccine is evaluated) at the same time of participating in this study. Participation in another observational or low-interventional clinical study at the same time is allowed.\n* Unable to give informed consent\n* Patient has severe anaemia\n* Patient received blood transfusion two weeks before sample collection\n* Blood sampling would compromise patients' overall health\n* Patients who are positive for Human Immunodeficiency Virus (HIV), Hepatitis B or Hepatitis C.\n* Patients who are alcoholic or drug abusers\n* Patients with a history or current evidence of any condition or abnormality that might confound the results of the study, or is not in the best interest of the patient to participate, in the opinion of the investigator.","25 Years","64 Years",{"count":139,"type":21},100,[56],"The goal of the COMBISCREEN project is to develop a fully molecular cervical screening and triage approach that is applicable on self-samples, which are an easily accessible and non-invasive source of biomarkers. The project allows a one-step screening and triage modality and thereby identifies women with clinically relevant disease that are in need of treatment.",[27,143,144,145],"Uterine Cervical Dysplasia","Human Papilloma Virus","HPV-Related Cervical Carcinoma",[147,148,149,117,150,151,152],"biomarker","first-void urine","vaginal sample","triage","self-sampling","prevention","2024-09-13",{"date":155,"type":37},"2024-09-19",{"date":157,"type":37},"2024-03-28",{"date":159,"type":21},"2037-02-28",{"name":161,"class":92},"Universiteit Antwerpen"]